depemokimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
depemokimab

GtoPdb Ligand ID: 14305

Synonyms: depemokimab-ulaa | Exdensur® | GSK-3511294 | GSK3511294

depemokimab is an approved drug

Compound class: Antibody

Comment: Depemokimab (GSK-3511294) is a humanized IgG1κ monoclonal; antibody that targets interleukin 5 (IL-5). It binds to the same epitope as, but with higher affinity mepolizumab [4].

References
1. Gill BA, Ijaz A, Fatima N, Ahmed A, Noor A, Sharif S, Fatima I, Saeeda A, Devi H, Saddique MN. (2025) Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials. BMC Immunol, 27 (1): 2. [PMID:41331792]
2. Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luíz Martinez G, Dymek L et al.. (2024) Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med, 391 (24): 2337-2349. [PMID:39248309]
3. Pillay S. (2025) Depemokimab in eosinophilic asthma - a new era in biological therapy?. Afr J Thorac Crit Care Med, 31 (1): 42. [PMID:40260270]
4. Singh D, Fuhr R, Bird NP, Mole S, Hardes K, Man YL, Cahn A, Yancey SW, Pouliquen IJ. (2022) A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol, 88 (2): 702-712. [PMID:34292606]

References

1. Gill BA, Ijaz A, Fatima N, Ahmed A, Noor A, Sharif S, Fatima I, Saeeda A, Devi H, Saddique MN. (2025)
Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.
BMC Immunol, 27 (1): 2. [PMID:41331792]

2. Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luíz Martinez G, Dymek L et al.. (2024)
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype.
N Engl J Med, 391 (24): 2337-2349. [PMID:39248309]

3. Pillay S. (2025)
Depemokimab in eosinophilic asthma - a new era in biological therapy?.
Afr J Thorac Crit Care Med, 31 (1): 42. [PMID:40260270]

4. Singh D, Fuhr R, Bird NP, Mole S, Hardes K, Man YL, Cahn A, Yancey SW, Pouliquen IJ. (2022)
A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.
Br J Clin Pharmacol, 88 (2): 702-712. [PMID:34292606]